Double maintains 1 strategies that include MLYS - Mineralys Therapeutics, Inc.
Current Value
$13.581 Year Return
Current Value
$13.581 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PTGX | 56.35% | $3.08B | +44.06% | 0.00% |
| OCUL | 34.83% | $1.58B | +53.80% | 0.00% |
| ACLX | 34.72% | $3.67B | +16.69% | 0.00% |
| APGE | 34.63% | $2.17B | -9.25% | 0.00% |
| CRNX | 33.60% | $2.75B | -39.10% | 0.00% |
| EYPT | 33.16% | $684.68M | +13.46% | 0.00% |
| ALB | 33.02% | $8.26B | -22.38% | 2.31% |
| KN | 32.94% | $1.57B | +3.26% | 0.00% |
| KRYS | 31.32% | $4.14B | -25.96% | 0.00% |
| XNCR | 31.31% | $588.58M | -55.05% | 0.00% |
| CGON | 31.30% | $1.98B | -19.15% | 0.00% |
| MWA | 31.19% | $3.87B | +36.60% | 1.07% |
| ALKS | 31.17% | $4.84B | +22.21% | 0.00% |
| ORA | 31.09% | $5.24B | +22.43% | 0.55% |
| FBIO | 30.81% | $57.07M | +12.21% | 0.00% |
| CRSP | 30.31% | $4.73B | -0.38% | 0.00% |
| IPGP | 30.27% | $3.11B | -13.56% | 0.00% |
| IOVA | 30.21% | $591.06M | -76.53% | 0.00% |
| KOD | 30.10% | $205.78M | +54.15% | 0.00% |
| CELC | 29.90% | $507.41M | -21.73% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 37.30% | $4.90B | 0.35% |
| PBE | 36.59% | $228.63M | 0.58% |
| IBB | 33.94% | $5.44B | 0.45% |
| XPH | 32.62% | $150.90M | 0.35% |
| ARKG | 32.61% | $1.06B | 0.75% |
| GNOM | 31.96% | $46.32M | 0.5% |
| FBT | 30.38% | $1.02B | 0.54% |
| IWC | 30.01% | $847.74M | 0.6% |
| IWO | 29.47% | $11.87B | 0.24% |
| PINK | 29.01% | $130.93M | 0.5% |
| BBH | 28.95% | $340.09M | 0.35% |
| CALF | 28.55% | $4.30B | 0.59% |
| IWM | 28.54% | $66.85B | 0.19% |
| PTH | 28.44% | $97.73M | 0.6% |
| VTWO | 28.29% | $12.85B | 0.07% |
| KJAN | 27.41% | $287.30M | 0.79% |
| GSSC | 27.17% | $597.33M | 0.2% |
| DRIV | 27.10% | $313.15M | 0.68% |
| COWZ | 26.72% | $21.04B | 0.49% |
| PBW | 26.62% | $293.05M | 0.65% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MDLZ | <0.01% | $88.29B | +4.52% | 2.77% |
| RACE | -0.02% | $87.15B | +14.72% | 0.69% |
| XGN | 0.03% | $151.93M | +267.72% | 0.00% |
| TSN | 0.04% | $19.46B | -0.36% | 3.57% |
| AVNW | 0.04% | $309.09M | -11.16% | 0.00% |
| GO | 0.04% | $1.26B | -40.31% | 0.00% |
| SAM | 0.14% | $2.21B | -31.49% | 0.00% |
| NI | -0.15% | $18.36B | +34.90% | 2.79% |
| TEO | 0.15% | $1.12B | +24.03% | 0.00% |
| ARHS | 0.20% | $1.29B | -37.47% | 0.00% |
| LUMN | 0.20% | $4.64B | +326.42% | 0.00% |
| AGRO | -0.20% | $932.94M | -4.80% | 3.73% |
| TBRG | 0.22% | $345.39M | +131.75% | 0.00% |
| SATS | -0.26% | $9.39B | +84.00% | 0.00% |
| KNTK | 0.26% | $2.61B | +2.66% | 7.18% |
| LRN | -0.26% | $5.93B | +105.34% | 0.00% |
| CCEP | 0.28% | $44.23B | +32.93% | 2.26% |
| CODI | 0.29% | $492.80M | -69.15% | 15.22% |
| FLYW | 0.32% | $1.43B | -28.46% | 0.00% |
| HUM | -0.33% | $28.66B | -36.39% | 1.50% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -16.81% | $312.42M | 1.43% |
| TAIL | -15.74% | $95.09M | 0.59% |
| VIXY | -15.51% | $185.99M | 0.85% |
| JMST | -13.19% | $4.08B | 0.18% |
| BSMW | -12.88% | $107.54M | 0.18% |
| XHLF | -12.88% | $1.73B | 0.03% |
| SGOV | -10.77% | $50.43B | 0.09% |
| STOT | -10.11% | $252.89M | 0.45% |
| FLMI | -9.64% | $735.98M | 0.3% |
| TBLL | -9.20% | $2.12B | 0.08% |
| CLIP | -8.89% | $1.54B | 0.07% |
| IBDQ | -8.75% | $2.96B | 0.1% |
| XBIL | -8.50% | $784.40M | 0.15% |
| XONE | -8.39% | $627.68M | 0.03% |
| MLN | -8.34% | $514.61M | 0.24% |
| FXY | -8.20% | $812.67M | 0.4% |
| BILS | -7.08% | $3.80B | 0.1356% |
| PZA | -6.86% | $2.84B | 0.28% |
| USFR | -6.69% | $18.57B | 0.15% |
| HTAB | -6.45% | $411.25M | 0.39% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SHYD | -0.01% | $331.76M | 0.35% |
| SMMU | -0.02% | $891.96M | 0.35% |
| HYMB | -0.03% | $2.63B | 0.35% |
| IBTO | 0.06% | $349.97M | 0.07% |
| JMUB | 0.07% | $3.06B | 0.18% |
| OILK | 0.08% | $74.73M | 0.69% |
| DFNM | -0.09% | $1.58B | 0.17% |
| UTEN | -0.11% | $210.22M | 0.15% |
| USO | -0.14% | $1.17B | 0.6% |
| LMBS | 0.15% | $5.10B | 0.64% |
| SUB | 0.16% | $9.92B | 0.07% |
| HYD | 0.16% | $3.31B | 0.32% |
| IBTM | -0.17% | $315.31M | 0.07% |
| AGZ | -0.17% | $610.34M | 0.2% |
| IBD | 0.19% | $389.24M | 0.43% |
| TPMN | 0.23% | $30.94M | 0.65% |
| VGIT | -0.28% | $31.66B | 0.04% |
| SCHR | 0.29% | $10.83B | 0.03% |
| STPZ | -0.30% | $443.02M | 0.2% |
| VTEB | -0.38% | $37.79B | 0.03% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| K | -18.60% | $27.53B | +40.77% | 2.87% |
| RKT | -18.20% | $2.08B | +9.58% | 0.00% |
| MRX | -16.97% | $2.73B | +98.75% | 1.47% |
| PULM | -14.56% | $23.96M | +218.45% | 0.00% |
| STG | -13.67% | $31.09M | -22.74% | 0.00% |
| COKE | -12.06% | $8.90B | +5.73% | 7.04% |
| BTCT | -11.12% | $25.33M | +62.02% | 0.00% |
| FAT | -9.81% | $43.84M | -8.77% | 11.16% |
| CLX | -8.78% | $15.52B | -4.47% | 3.86% |
| WELL | -8.17% | $99.24B | +44.77% | 1.77% |
| FLUT | -7.39% | $50.40B | +43.39% | 0.00% |
| PARAA | -7.32% | $15.51B | +8.80% | 0.87% |
| CL | -7.24% | $74.67B | -5.05% | 2.19% |
| LFVN | -7.20% | $177.75M | +150.80% | 1.17% |
| CAH | -7.05% | $39.25B | +71.28% | 1.23% |
| POST | -6.99% | $5.94B | +2.82% | 0.00% |
| CNC | -6.26% | $16.22B | -50.41% | 0.00% |
| FICO | -6.12% | $41.46B | +8.62% | 0.00% |
| VHC | -6.09% | $57.60M | +131.12% | 0.00% |
| ACI | -6.02% | $12.50B | +13.93% | 2.44% |
Yahoo
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Yahoo
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is one of the 12 Small Cap Stocks with High Upside Potential. On June 17, Mineralys Therapeutics, Inc. (NASDAQ:MLYS) reported positive topline data from its Phase 2 Explore-CKD trial of lorundrostat. The company achieved positive topline data for the ongoing trials of lorundrostat for the treatment of subjects with hypertension and […]
Finnhub
Mineralys Therapeutics, Inc. dropped from Russell 3000 Value Index...
Yahoo
– The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension – – Lorundrostat 50 mg once daily demonstrated clinically meaningful reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 and a 19.0 mmHg reduction at Week 12 – – Lorundrostat was generally well-tolerated; and treatment-emergent adverse events were mostly mild, transient, and resolved without intervention – RADNOR,
Finnhub
Mineralys Therapeutics, Inc. announced the publication of the positive results from the pivotal Phase 3 Launch-HTN trial in the Journal of the American Medical Association . The manuscript titled...
Finnhub
Mineralys Therapeutics, Inc. dropped from Russell 2500 Value Index...
